While in a cohort of 12 COVID-19 patients, circulating Ang II levels were markedly elevated compared to healthy controls (linearly correlated with viral load; Liu et al., 2020), it was showed that decreasing Ang II with ACE inhibitors and ARBs can improve Ang 1–7 and attenuate inflammation, fibrosis, and lung injury (South et al., 2020). Here, ACE is linked to COVID-19.